Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781025 | 1.00 | MAOB (0.61) | MAOBCA1CA2ARG2IDO1 | |
| SCHEMBL10864400 | 0.88 | IDO1 (0.47) | MAOBCA1CA2ARG2IDO1 | |
| SCHEMBL27597502 | 0.87 | MAOB (0.47) | MAOBCA1CA2ARG2IDO1 | |
| SCHEMBL217134 | 0.81 | MAOB (0.67) | MAOBCA1CA2ARG2IDO1 | |
| SCHEMBL1975588 | 0.81 | MAOB (0.67) | MAOBCA1CA2ARG2IDO1 | |
| SCHEMBL2512151 | 0.80 | ATM (0.50) | HTTATMALDH1A1 | |
| SCHEMBL5021267 | 0.80 | TP53 (0.37) | MAOBCA2IDO1TP53TSHR | |
| SCHEMBL1781780 | 0.80 | AGXT (0.45) | MAOBCA1CA2IDO1TP53 | |
| SCHEMBL1784538 | 0.80 | TP53 (0.37) | MAOBCA2IDO1TP53TSHR | |
| SCHEMBL5021265 | 0.80 | AGXT (0.45) | MAOBCA1CA2IDO1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528960-A | Method for preparing allylsilane compound through enol ether double bond displacement | 成都泰和伟业生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118166369-A | Electrochemical synthesis method of E-type styrene derivative | 华东师范大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-2995950-B1 | METHOD RELATING TO SWEETNESS ENHANCEMENT | GIVAUDAN SA (CH) | 2024-01-17 | — | — | EP | disclosed |
| CN-116535418-A | Synthesis method and application of chiral N- (1-substituted-allyl) amine | 西安交通大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-09 | — | — | US | disclosed |
| CN-111087352-B | Preparation method of 3-trifluoroalkyl quinoxalinone compound | 曲阜师范大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-112142680-B | Method for synthesizing 3-trifluoroalkyl quinoxalinone by visible light catalysis | 曲阜师范大学 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021113473-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10647733-B2 | Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations | THE UNIVERSITY OF CHICAGO (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111087352-A | Preparation method of 3-trifluoroalkyl quinoxalinone compound | 曲阜师范大学 | 2020-05-01 | — | — | CN | disclosed |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6552023-B2 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | disclosed |
| US-20010036961-A1 | Substituted alkylene diamine compounds | CV THERAPEUTICS, INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001066097-A2 | ACTIVE SUBSTANCE DIRECTED AGAINST MICROBES OF THE GENUS PSEUDOMONAS | DRAGOCO GERBERDING & CO. AG (DE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062711-A2 | SUBSTITUTED ALKYLENE DIAMINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-5403863-A | Scolytid repellant | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1995-04-04 | — | — | US | disclosed |
| US-4062862-A | MUSCLE RELAXANT | NIPPON CHEMIPHAR CO., LTD. (JA) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647733-B2 | Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations | NCLN, MDH1, NNMT | MAOB 1387/4885CA1 1109/4885CA2 1227/4885 |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | TNNC1, ATP2A1, ATP2A2 | MAOB 3240/4885CA1 3238/4885CA2 1466/4885 |
| US-20010036961-A1 | Substituted alkylene diamine compounds | TNNC1, CPT1B, TNNI3 | MAOB 2112/4885CA1 2296/4885CA2 1907/4885 |
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | GCKR, G6PC1, GPR119 | MAOB 4866/4885CA1 2816/4885CA2 1158/4885 |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | ATP2A1, ATP2A3, ATP2A2 | MAOB 3783/4885CA1 3996/4885CA2 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.